Review of CMS’ coverage with evidence development program exposes a need to improve program transparency and clarify requirements and timetables for reporting to improve access to novel therapies.
Sana M. Al-Khatib, MD, MHS
Advertisement
Articles by Sana M. Al-Khatib, MD, MHS
Advertisement
Latest Updated Articles
Conditional Economic Incentives Could Be Effective in Improving Adherence to Long-Acting PrEP in Transgender AdultsPublished: August 18th 2025 | Updated: August 25th 2025
Semaglutide Not Associated With Increased Risk of Eye DisordersPublished: August 19th 2025 | Updated: August 22nd 2025
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?Published: June 6th 2025 | Updated: August 18th 2025
Report Reveals Mounting Burdens of Drug Shortages on US Health SystemPublished: June 27th 2025 | Updated: July 1st 2025
Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPPPublished: February 20th 2025 | Updated: February 21st 2025
FDA Proposal Aims to Reduce Smoking Addiction and SCLC CasesPublished: January 16th 2025 | Updated: January 29th 2025
Advertisement
Advertisement
Trending on AJMC
1
West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations
2
Cumulative Atropine Not Associated With Increased Risk of Ocular Events in Children With Myopia
3
Hospitals in Underserved Communities Less Likely to Adopt Health Information Technology
4
Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
5
